Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.
about
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.NaRoles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceThe role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populationsGlycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition?Animal models of leukemia: any closer to the real thing?AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicinInhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cellsgeneCommittee: a web-based tool for extensively testing the discriminatory power of biologically relevant gene sets in microarray data classificationHyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells.AICAR inhibits proliferation and induced S-phase arrest, and promotes apoptosis in CaSki cells.Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Akt Cys-310-targeted inhibition by hydroxylated benzene derivatives is tightly linked to their immunosuppressive effectsRas oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cellsOncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virusTCR-induced Akt serine 473 phosphorylation is regulated by protein kinase C-alphaSoft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha.Akt1 mediates neuronal differentiation in zebrafish via a reciprocal interaction with notch signalingHigh-resolution kinetics of cytokine signaling in human CD34/CD117-positive cells in unfractionated bone marrow.Contribution of bone microenvironment to leukemogenesis and leukemia progression.Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survivalTargeting PML-RARα and Oncogenic Signaling Pathways by Chinese Herbal Mixture Tien-Hsien Liquid in Acute Promyelocytic Leukemia NB4 CellsLow expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo.Rational Combinations of Targeted Agents in AMLA Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaLow expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.Analyzing gene expression profile in K562 cells exposed to sodium valproate using microarray combined with the connectivity map databaseA PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis.EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expressionTemporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppressionPhosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients.The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.PKCδ Regulates Translation Initiation through PKR and eIF2α in Response to Retinoic Acid in Acute Myeloid Leukemia CellsPotentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways.
P2860
Q24597616-5F71E65B-36DD-4624-A943-81049E960D87Q24645668-4214503C-688A-49F1-99F2-02D5F1DB23F3Q24646816-11654902-F43F-442D-8033-C139E071BADBQ26742115-47C106B3-3220-49DC-8126-2E851603FDA3Q27026520-2433902F-A2B4-466B-A115-617FB5BC5E83Q28484890-63140D16-FBA8-4831-A0B7-0FD3AFF54915Q28512494-4F19C81B-6B23-45C9-A0E2-9B98B886DCEEQ30570393-D705A505-BFF3-4B4D-AD7A-EB95B370B040Q31037798-1B9CCA0A-D7DE-4707-980A-479836D0DA74Q33306763-058F2A1C-3751-446A-93E1-5B1EC6716565Q33493174-FCCC670D-FED3-4D49-BFCF-A5A5E5678792Q33744734-53066D87-E320-48A1-846A-CB6D0AF4ADACQ33779805-5AE31279-2878-4A3B-B84B-B8C06D55C3ACQ33823577-6FA50586-144F-440E-8ABB-AA8678BE1308Q33840360-44800B33-F0B0-4BDC-AE73-65DFBC0B3673Q33889083-2008C1BE-4A73-4A73-8495-E67A9365189FQ33895494-B077DD66-90E4-4A34-B1DF-619FEEFB4441Q34144420-1ABB9F4E-7A9D-4F10-ABD1-242EB701CC04Q34240979-7D6CDB4C-540F-4818-8AD6-61BDAC447B9AQ34559260-5B32CA46-84F3-481C-8958-43CE0CB3895CQ34924515-C12ACFF7-54E7-4588-AEBF-F695F2765336Q35037058-D6C475B3-6B83-4D2D-A0EE-B228518DB96BQ35091507-48F948A8-2246-4500-8D2E-0FB78612B334Q35096551-512ACA48-E2E6-4EFD-A9ED-A3F74C6D1A05Q35109736-8DB22428-5F8E-4D71-AEB9-2EA22B4AC267Q35316765-A99D2E5F-8B7F-4859-8C5C-080BAA29161AQ35664310-5B21E78F-3DC6-4991-8F9A-6F8A7616C599Q35750491-874F6D89-FDC3-40E6-B9E7-875EE14B8809Q35752048-EB84189D-47A5-4D3B-B2EE-2C84A95987CDQ35794120-5D5F510A-6210-4D90-B1DE-6B0671B3CF0AQ36026603-51815FB6-8E53-4E22-974A-2B0A9AED2B61Q36139665-4AE427E0-FB9E-4112-99FD-7EF0CAFCD40DQ36175652-ADF84970-94F2-4C08-BC29-89B10DD5DEADQ36248716-E30FAB04-7BA8-4C78-BED8-6C4041DE2689Q36324321-4C2D42D1-1DA1-442D-B240-435422BA86ACQ36379644-9916EA25-A631-4DB3-8B60-594F9B6ADB3EQ36422120-2147F221-C836-4321-80E4-E61F9FB47310Q36508937-DF99BA7C-7362-4D41-97F6-EE44B465EE2FQ36557300-7A7DC6D7-D90A-47CC-89A0-DE801532685EQ36610111-E88EBA76-545A-4730-AAD9-FC4BD7812E28
P2860
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Phosphoinositide 3-kinase/Akt ...... human acute myeloid leukemia.
@ast
Phosphoinositide 3-kinase/Akt ...... human acute myeloid leukemia.
@en
type
label
Phosphoinositide 3-kinase/Akt ...... human acute myeloid leukemia.
@ast
Phosphoinositide 3-kinase/Akt ...... human acute myeloid leukemia.
@en
prefLabel
Phosphoinositide 3-kinase/Akt ...... human acute myeloid leukemia.
@ast
Phosphoinositide 3-kinase/Akt ...... human acute myeloid leukemia.
@en
P2093
P2860
P356
P1433
P1476
Phosphoinositide 3-kinase/Akt ...... r human acute myeloid leukemia
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404245
P577
2006-06-01T00:00:00Z